<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02016508</url>
  </required_header>
  <id_info>
    <org_study_id>NCT 4619792013</org_study_id>
    <secondary_id>4619792013</secondary_id>
    <nct_id>NCT02016508</nct_id>
  </id_info>
  <brief_title>Safety Study of Use of Autologous Bone Marrow Derived Stem Cell in Treatment of Age Related Macular Degeneration</brief_title>
  <official_title>Intravitreal Injection of Human Bone Marrow Derived Mesenchymal Stem Cell in Patients With Dry Age-related Macular Degeneration(AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Al-Azhar University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hassan , Hosny , M.D. M.Sc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samour , Hany M.D. M.Sc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ismail , Mahmoud M.D. M.Sc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Higazy , Hasan M.D. M.Sc</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abou el kheir, Wael, M.D. M.Sc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gabr, Hala , M.D. M.Sc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bakry, Sayed , phD. M.Sc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Al-Azhar University</source>
  <brief_summary>
    <textblock>
      The purpose of this Phase I/II study is to investigate the safety and preliminary efficacy of
      unilateral intravitreally transplantation of adult bone marrow stem cells in subjects with
      geographic atrophy secondary to age-related macular degeneration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label investigation of the safety and preliminary efficacy of
      unilateral intravitreal injection of autologous bone marrow stem cells in subjects with
      Geographic Atrophy secondary to Age-Related Macular Degeneration (AMD). Subjects will be
      enrolled based on specific inclusion/exclusion criteria and evaluated at regular post
      transplant intervals.

      Human central nervous system -stem cells will be transplanted by a vitreoretinal surgeon. The
      transplantation will be conducted in the eye with the inferior best-corrected visual acuity
      (BCVA) (i.e., the Study Eye). Only the Study Eye will undergo transplantation. The adult bone
      marrow stem cells will be administered into the vitreous cavity through a standard surgical
      approach.

      Moxifloxacin 300 mg(once per day ) will be administered orally to all subjects for a period
      of five days ( 2 days pre and post operatively) .

      Subjects will be monitored frequently for a total of one year after adult bone marrow stem
      cells cell injection .
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of subjects with adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Descriptive analysis of frequency and types of adverse events experienced by each subject during the study period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of visual function changes from the base line</measure>
    <time_frame>6 months</time_frame>
    <description>assessment will include Change in the mean of BCVA, Optical Coherence Tomography imaging, fluorescein angiography, slitlamp examination with fundus photography, Electroretinographic evidence (mfERG) showing enhanced activity in the location</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>autologous bone marrow stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>use of autologous bone marrow derived stem cells as intravitreal injection in AMD patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>autologous bone marrow derived stem cells</intervention_name>
    <description>intravitreal injection of autologous bone marrow stem cells in 0.1 ml volume</description>
    <arm_group_label>autologous bone marrow stem cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of age-related macular degeneration with geographic atrophy (GA)

          -  Only patients with a specific degree and extent of GA will be eligible

          -  Subjects with best-corrected visual acuity (BCVA) of less than or equal to 20/400 in
             the Study Eye

          -  No prior or current choroidal neovascularization in either eye

          -  Able to provide written informed consent prior to any study related procedures

          -  Agree to comply in good faith with all conditions of the study and to attend all
             required study visits

        Exclusion Criteria:

          -  Prior vitreal or retinal surgery in the previous 6 months

          -  Glaucoma

          -  Atrophic macular disease of any other cause

          -  Diabetic retinopathy or diabetic macular edema in either eye

          -  Previous organ, tissue or bone marrow transplantation

          -  Autoimmune disease

          -  Allergy to moxifloxacin

          -  Current or prior malignancy (or is on chemotherapy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Abdelhakim mohamed safwat, M.D.</last_name>
    <phone>+201005151919</phone>
    <email>abdelhakimsafwat@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Al-Azhar university medical school (Benin-cairo) ophthalmology department</name>
      <address>
        <city>Cairo</city>
        <state>Nasr city</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Abdelhakim Mohamed Safwat, Msc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2013</study_first_submitted>
  <study_first_submitted_qc>December 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2013</study_first_posted>
  <last_update_submitted>December 20, 2013</last_update_submitted>
  <last_update_submitted_qc>December 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Al-Azhar University</investigator_affiliation>
    <investigator_full_name>abdelhakim mohamed safwat</investigator_full_name>
    <investigator_title>assistant lecturer ophthalmology department al-azhar university</investigator_title>
  </responsible_party>
  <keyword>Adult bone marrow stem cells</keyword>
  <keyword>AMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

